222 related articles for article (PubMed ID: 34264298)
1. Antifungal susceptibility of clinical Cryptococcus gattii isolates from Colombia varies among molecular types.
Firacative C; Escandón P
Med Mycol; 2021 Nov; 59(11):1122-1125. PubMed ID: 34264298
[TBL] [Abstract][Full Text] [Related]
2. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
5. First report of cryptococcosis due to Cryptococcus gattii sensu stricto VGI in an Ivorian HIV negative patient.
Bellet V; Kassi FK; Krasteva D; Roger F; Drakulovski P; Mossou C; Kouakou GA; Doumbia A; Delaporte E; Menan H; Bertout S
J Mycol Med; 2021 Jun; 31(2):101113. PubMed ID: 33540367
[TBL] [Abstract][Full Text] [Related]
6. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
7. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
Lee GA; Arthur I; Merritt A; Leung M
Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
9. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains.
Silva DC; Martins MA; Szeszs MW; Bonfietti LX; Matos D; Melhem MS
Diagn Microbiol Infect Dis; 2012 Apr; 72(4):332-9. PubMed ID: 22341512
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of the epidemiology and clinical manifestations of Cryptococcus gattii infections in Colombia from 1997-2011.
Lizarazo J; Escandón P; Agudelo CI; Firacative C; Meyer W; Castañeda E
PLoS Negl Trop Dis; 2014; 8(11):e3272. PubMed ID: 25411779
[TBL] [Abstract][Full Text] [Related]
12. MLST and Whole-Genome-Based Population Analysis of Cryptococcus gattii VGIII Links Clinical, Veterinary and Environmental Strains, and Reveals Divergent Serotype Specific Sub-populations and Distant Ancestors.
Firacative C; Roe CC; Malik R; Ferreira-Paim K; Escandón P; Sykes JE; Castañón-Olivares LR; Contreras-Peres C; Samayoa B; Sorrell TC; Castañeda E; Lockhart SR; Engelthaler DM; Meyer W
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004861. PubMed ID: 27494185
[TBL] [Abstract][Full Text] [Related]
13. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.
Herkert PF; Hagen F; de Oliveira Salvador GL; Gomes RR; Ferreira MS; Vicente VA; Muro MD; Pinheiro RL; Meis JF; Queiroz-Telles F
Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1803-1810. PubMed ID: 27477855
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
Chong HS; Dagg R; Malik R; Chen S; Carter D
J Clin Microbiol; 2010 Nov; 48(11):4115-20. PubMed ID: 20844209
[TBL] [Abstract][Full Text] [Related]
16. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility.
Lockhart SR; Iqbal N; Bolden CB; DeBess EE; Marsden-Haug N; Worhle R; Thakur R; Harris JR;
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):144-8. PubMed ID: 22494557
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China.
Wu SY; Kang M; Liu Y; Chen ZX; Xiao YL; He C; Ma Y
Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):287-295. PubMed ID: 32895755
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.
Yang ML; Uhrig J; Vu K; Singapuri A; Dennis M; Gelli A; Thompson GR
Antimicrob Agents Chemother; 2015 Dec; 60(3):1202-7. PubMed ID: 26643330
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system infection due to Cryptococcus gattii sensu lato in India: Analysis of clinical features, molecular profile and antifungal susceptibility.
Lahiri Mukhopadhyay S; Bahubali VH; Manjunath N; Swaminathan A; Maji S; Palaniappan M; Parthasarathy S; Chandrashekar N
Mycoses; 2017 Nov; 60(11):749-757. PubMed ID: 28736880
[TBL] [Abstract][Full Text] [Related]
20. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
